Pfizer Caduet Sell-In Is $28 Mil.; Is Streak Of Weak Launches Ending?
This article was originally published in The Pink Sheet Daily
Executive Summary
Pfizer posts $11 bil. in pharma sales during first quarter, but few recent launches (other than Bextra) are significant contributors. Inspra is off to a slow start, though Pfizer maintains prescriptions are growing "steadily."
You may also be interested in...
Spiriva Off To “Great Start,” But Caduet Will Take Time
The launch of Caduet is moving more slowly than Pfizer had hoped, the company acknowledged during its second quarter conference call July 21
Spiriva Off To “Great Start,” But Caduet Will Take Time
The launch of Caduet is moving more slowly than Pfizer had hoped, the company acknowledged during its second quarter conference call July 21
Caduet Launches At 15% Discount To Lipitor Plus Norvasc
Caduet 5 mg/10 mg lists for $2.88 per dose; all other strengths are $3.94 per dose. "U Share" Card offers Caduet for 20% less than same strengths of Lipitor and Norvasc purchased separately.